The stock of BeOne Medicines Ltd ADR (NASDAQ: ONC) has increased by 5.51 when compared to last closing price of 262.41.Despite this, the company has seen a gain of 7.73% in its stock price over the last five trading days. businesswire.com reported 2025-06-12 that SAN CARLOS, Calif.–(BUSINESS WIRE)—- $ONC #BeOne–BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which ha.
Is It Worth Investing in BeOne Medicines Ltd ADR (NASDAQ: ONC) Right Now?
Moreover, the 36-month beta value for ONC is 0.30. Analysts have varying opinions on the stock, with 15 analysts rating it as a “buy,” 8 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ONC is 108.59M and currently, short sellers hold a 1.87% of that float. On June 12, 2025, ONC’s average trading volume was 440.82K shares.
ONC’s Market Performance
ONC’s stock has seen a 7.73% increase for the week, with a 23.20% rise in the past month and a 8.76% gain in the past quarter. The volatility ratio for the week is 1.69%, and the volatility levels for the past 30 days are at 1.47% for BeOne Medicines Ltd ADR. The simple moving average for the past 20 days is 11.93% for ONC’s stock, with a 24.43% simple moving average for the past 200 days.
Analysts’ Opinion of ONC
Many brokerage firms have already submitted their reports for ONC stocks, with RBC Capital Mkts repeating the rating for ONC by listing it as a “Outperform.” The predicted price for ONC in the upcoming period, according to RBC Capital Mkts is $312 based on the research report published on April 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ONC reach a price target of $320, previously predicting the price at $207. The rating they have provided for ONC stocks is “Buy” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ONC, setting the target price at $300 in the report published on December 03rd of the previous year.
ONC Trading at 14.25% from the 50-Day Moving Average
After a stumble in the market that brought ONC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.83% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ONC starting from TITUS BENJAMIN BALL, who proposed sale 134 shares at the price of $258.36 back on Jun 11 ’25. After this action, TITUS BENJAMIN BALL now owns shares of BeOne Medicines Ltd ADR, valued at $34,620 using the latest closing price.
Lee Chan Henry, the SVP, General Counsel of BeOne Medicines Ltd ADR, sale 700 shares at $256.11 during a trade that took place back on Jun 06 ’25, which means that Lee Chan Henry is holding 0 shares at $179,280 based on the most recent closing price.
Stock Fundamentals for ONC
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.85 for the gross margin
The net margin for BeOne Medicines Ltd ADR stands at -0.09. The total capital return value is set at -0.08. Equity return is now at value -11.44, with -6.82 for asset returns.
Based on BeOne Medicines Ltd ADR (ONC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21.
Currently, EBITDA for the company is -396.44 million with net debt to EBITDA at 12.96. When we switch over and look at the enterprise to sales, we see a ratio of 6.22. The receivables turnover for the company is 5.6for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.96.
Conclusion
To wrap up, the performance of BeOne Medicines Ltd ADR (ONC) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
